Shanghai Celgen Biopharmaceutical co, Ltd ("Celgen"), is a leading bio-similar biopharmaceuticals drugs developer and manufacture in China mainly focused on Inflammation, Oncology and Metabolic Disease. Celgen’s main product is a Monoclonal Antibody (MAB) called Etanercept a Generic version of Amgen’s Enbrel used for the treatment of inflammatory conditions such as Rheumatoid arthritis, Juvenile rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis.